Apollomics (APLM) Accumulated Expenses (2022 - 2025)
Apollomics (APLM) posted quarterly Accumulated Expenses of $6.1 million for Q4 2025, down 52.23% quarter-over-quarter from $12.8 million in Q2 2023.
Apollomics (APLM) Accumulated Expenses (2022 - 2025) Analysis & Trends
Apollomics (APLM) has reported Accumulated Expenses for 3 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses changed N/A year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $6.1 million, changed N/A from the prior year.
- Accumulated Expenses retreated to $6.1 million in Q4 2025 per APLM's latest filing, from $12.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $12.8 million in Q2 2023 and bottomed at $6.1 million in Q4 2025.
- Historically, Accumulated Expenses has averaged $10.2 million across 3 years, with a median of $11.7 million in 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Apollomics | 35.18 Mn | 31.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.12 Mn |
| Jun 30, 2023 | 12.80 Mn |
| Dec 31, 2022 | 11.68 Mn |